Concord Medical Services (CCM)
NYSE:CCM
Want to see CCM full AI Analyst Report?
Top Page
Concord Medical Services
(NYSE:CCM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$4.50
▼(-6.25% Downside)
Action:DowngradedDate:01/27/26
The score is primarily weighed down by severe financial stress (declining revenue, persistent losses, negative equity, and negative operating/free cash flow). Technicals are only neutral and do not offset the weak fundamentals, while valuation is constrained by a negative P/E and lack of dividend support.
Positive Factors
Market Position
CCM's positioning as a leading provider of cancer treatment and diagnostics in China indicates durable demand and scale advantages. A broad network of centers supports referral flows, payer relationships and operational leverage that can sustain volume and service breadth over the medium term.
Negative Factors
Revenue and Margin Erosion
A steep revenue decline combined with negative gross profit and EBIT margins undermines the business's ability to cover fixed costs and invest in equipment and personnel. Persistent top-line contraction threatens long-term scale economics and could force service reductions or restructurings.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Position
CCM's positioning as a leading provider of cancer treatment and diagnostics in China indicates durable demand and scale advantages. A broad network of centers supports referral flows, payer relationships and operational leverage that can sustain volume and service breadth over the medium term.
Read all positive factors
Concord Medical Services (CCM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$16.72M
Dividend YieldN/A
Average Volume (3M)25.64K
Price to Earnings (P/E)―
Beta (1Y)0.12
Revenue Growth-22.38%
EPS Growth56.66%
CountryUS
Employees595
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)-9.83
Shares Outstanding2,815,458
10 Day Avg. Volume72,657
30 Day Avg. Volume25,639
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.01
P/FCF Ratio>-0.01
Enterprise Value/Market Cap218.30
Enterprise Value/Revenue9.98
Enterprise Value/Gross Profit-87.20
Enterprise Value/Ebitda-10.18
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Concord Medical Services Business Overview & Revenue Model
Company Description
Concord Medical Services Holdings Limited, together its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. The company operates in two segments, Network and Hospital. Its services inc...
How the Company Makes Money
Concord Medical Services generates revenue primarily through its cancer treatment services, including radiation therapy, diagnostic imaging, and related healthcare services. The company charges patients and insurance providers for these services, ...
Concord Medical Services Financial Statement Overview
Summary
Income Statement
15
Very Negative
Balance Sheet
10
Very Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 365.76M | 383.96M | 537.40M | 472.08M | 485.63M | 223.01M |
| Gross Profit | -41.85M | -79.16M | -76.61M | -152.41M | -56.90M | 13.08M |
| EBITDA | -358.51M | -345.62M | -344.16M | -401.86M | -363.86M | -236.72M |
| Net Income | -163.12M | -308.24M | -297.66M | -489.66M | -271.43M | -309.99M |
Balance Sheet | ||||||
| Total Assets | 6.73B | 6.73B | 6.05B | 6.00B | 6.23B | 5.33B |
| Cash, Cash Equivalents and Short-Term Investments | 177.39M | 350.85M | 58.14M | 158.28M | 157.39M | 334.26M |
| Total Debt | 3.82B | 3.93B | 3.30B | 3.24B | 2.73B | 2.35B |
| Total Liabilities | 5.01B | 5.11B | 4.31B | 3.99B | 3.49B | 2.93B |
| Stockholders Equity | -2.24B | -2.28B | -2.12B | -1.86B | -1.37B | -662.96M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -808.58M | -392.17M | -600.47M | -1.12B | -734.47M |
| Operating Cash Flow | 0.00 | -397.75M | -276.47M | -216.69M | -359.31M | -229.77M |
| Investing Cash Flow | 0.00 | -593.44M | -47.68M | -118.79M | -565.98M | -533.88M |
| Financing Cash Flow | 0.00 | 1.15B | 257.65M | 383.09M | 642.45M | 1.14B |
Concord Medical Services Technical Analysis
Positive
4.80
Price Trends
3.75
Positive
3.98
Negative
4.72
Negative
Market Momentum
0.04
Negative
54.57
Neutral
51.63
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CCM, the sentiment is Positive. The current price of 4.8 is above the 20-day moving average (MA) of 3.82, above the 50-day MA of 3.75, and above the 200-day MA of 4.72, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 54.57 is Neutral, neither overbought nor oversold. The STOCH value of 51.63 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CCM.
Concord Medical Services Risk Analysis
Concord Medical Services disclosed 78 risk factors in its most recent earnings report. Concord Medical Services reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
We may have conflicts of interest with our subsidiary Concord Healthcare which is a stand-alone public company. Q4, 2023
2.
Concord Healthcare may need to raise more capital, which could dilute our equity stake or impose debt service obligations on Concord Healthcare, if such capital is available at all. Q4, 2023
Concord Medical Services Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $126.90M | 45.39 | 14.37% | ― | -47.67% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $69.85M | -0.16 | -71.45% | ― | -47.74% | -1056.93% | |
46 Neutral | $28.35M | 145.34 | 15.82% | 11.14% | -2.56% | -2181.76% | |
45 Neutral | $20.20M | -0.04 | -257.39% | ― | -2.76% | -1.22% | |
44 Neutral | $16.72M | -0.11 | ― | ― | -22.38% | 56.66% | |
44 Neutral | $8.85M | -5.59 | -8.75% | ― | -0.91% | -168.54% |
* Healthcare Sector Average
CCM
Concord Medical Services
3.85
-4.66
-54.76%
AMS
American Shared Hospital Services
1.34
-1.36
-50.37%
JYNT
Joint
8.86
-1.15
-11.49%
CCEL
Cryo-Cell International
3.52
-1.58
-30.97%
DCGO
DocGo
0.71
-1.52
-68.30%
PIII
P3 Health Partners
2.80
-6.19
-68.85%
Concord Medical Services Corporate Events
Concord Medical Announces 2025 Shareholder Meeting
Dec 2, 2025
On December 2, 2025, Concord Medical Services announced its 2025 annual general meeting of shareholders scheduled for December 29, 2025, in Beijing. The meeting will not involve any proposals for shareholder approval but will serve as a platform f...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.